A pre-clinical study utilizing EpCAM CAR T in a T murine AML model showed that Akt inhibition (MK2206) at the initial stage of CAR T manufacture enhanced the expansion of CAR T cells and CART efficacy in vivo (30). This evidence concerns the gene EPCAM and acute myeloid leukemia.